Reata Pharmaceuticals RETA 深 沪
等待开盘 05-21 09:30:00 美东时间
172.36
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 172.36
- 总市值 656.65万
- 52周最高 172.46
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 21.83
- 委 比 0.00%
- 总股本 3.81万
- 历史最高 257.965
- 量 比 0
- 振 幅 0.00%
- 历史最低 11.03
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates
NervGen Pharma Corp. reported progress on its NVG-291 clinical development, including FDA alignment on the RESTORE study parameters for chronic tetraplegia, ongoing CONNECT SCI biomechanical gait analyses, and plans to initiate the RESTORE study in mid-2026. The company listed on Nasdaq under 'NGEN' and strengthened its leadership team with key senior appointments. Financially, NervGen ended Q1 2026 with $16.6M in cash and investments, increased ...
05-18 11:15
Spruce Biosciences names Dale Hooks chief commercial officer
Spruce Biosciences names Dale Hooks chief commercial officer Spruce Biosciences appointed Dale Hooks as chief commercial officer. Hooks previously served as chief commercial officer at Applied Therapeutics and held senior commercial roles at Reata Pharmaceuticals and Clovis Oncology. He also held co
03-09 19:00
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
NervGen Pharma Corp. has appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President of Patient Advocacy and Clinical Affairs. Both bring extensive experience to support NervGen's lead therapeutic, NVG-291, which is advancing through clinical trials for spinal cord injury (SCI). Ruff, with over 30 years in regulatory affairs, will oversee the company's regulatory strategy, while McSherry will ensure p...
03-04 12:30
Drugmaker Biogen forecasts 2025 profit below expectations
Feb 12 (Reuters) - Biogen BIIB.O forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis. Investors s...
2025-02-12 19:45
华盛早报 | 马斯克迎关键一战！特斯拉Robotaxi今日来袭；11月不降息？美联储官员意外放鹰
今日10点，马斯克迎关键一战！特斯拉Robotaxi震撼来袭；支持11月不降息？美联储官员意外放鹰；因重阳节假期，港股今日休市>>
2024-10-11 08:31
Biogen posts Q2 beat as sales from Alzheimer’s drug pick up
Despite an earnings miss, Biogen (NASDAQ:BIIB) managed to slightly exceed Street forecasts with its Q2 2024 revenue as sales from its newly-approved Alzheimer's drug Leqembi gained momentum while its ...
2024-08-01 20:50
Biogen Completes Acquisition of Reata Pharmaceuticals
Reata acquisition bolsters Biogen's rare disease portfolio with the addition of...
2023-09-26 20:59
Japan's Regulatory Authority Approves Biogen/Eisai's Alzheimer Treatment Leqembi
Eisai Co Ltd (OTC: ESALY) (OTC: ESALF) and Biogen Inc (NASDAQ: BIIB) announced that humanized anti-soluble aggregated amyloid-beta (A&be
2023-09-25 22:41
Reata Pharmaceuticals Stockholders Approve Merger Transaction With Biogen Inc.
Reata Pharmaceuticals, Inc. (NASDAQ:RETA) ("Reata," the "Company," "our," "us," or "we"), a global, biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases,
2023-09-21 22:14
